Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2025 Feb;282(2):993-1003.
doi: 10.1007/s00405-024-08965-7. Epub 2024 Sep 11.

Comparison of prognosis between oncocytic thyroid carcinoma and follicular thyroid carcinoma: a population-based propensity score matching analysis

Affiliations
Comparative Study

Comparison of prognosis between oncocytic thyroid carcinoma and follicular thyroid carcinoma: a population-based propensity score matching analysis

Hao Peng et al. Eur Arch Otorhinolaryngol. 2025 Feb.

Abstract

Background: Oncocytic thyroid carcinoma (OTC) is a rare subtype of thyroid cancer known for its distinctive morphology and high likelihood of recurrence, setting it apart from follicular thyroid carcinoma (FTC). Despite this, there is limited research comparing the clinicopathological characteristics and outcomes of OTC and FTC.

Methods: We retrospectively searched through the Surveillance, Epidemiology, and End-Results (SEER) database (2004-2015) for histologically diagnosed OTC and FTC patients. Kaplan-Meier analysis, propensity score matching (PSM), univariate Cox proportional risk regression model, and subgroup analysis were employed to investigate the prognostic effect of clinicopathological features and treatment regimens on survival outcomes of OTC and FTC patients.

Results: 2329 OTC patients and 5679 FTC patients were included in the study. OTC patients were prone to older age, white race, lymph node metastasis, distal metastasis, extension and multiple primary tumors compared with FTC patients. After using a 1:1 PSM matching ratio, there were no significant differences in demographic and clinicopathological characteristics between the matched groups. Further Cox regression analysis showed that OTC patients had lower overall survival (OS) and cancer-specific survival (CSS) in contrast with FTC patients. Subgroup survival analysis suggested that the OTC patients were related to lower OS in subgroups including those over 55 years old, male sex, white ethnicity, extrathyroidal extension, single primary tumor, surgery and without chemotherapy compared with the FTC patients in these subgroups. In addition, the OTC patients were connected with lower CSS in subgroups including male sex, white ethnicity, married status, tumor size is less than 20 mm or more than 40 mm, N0 stage, localized stage, single primary tumor, surgery, radiotherapy, and without chemotherapy compared with the FTC patients in these subgroups. Meanwhile, the OTC patients had lower CSS compared to FTC patients regardless of age and extrathyroidal extension.

Conclusions: The results suggested that OTC patients have unique clinical features and poorer prognoses compared to FTC patients. Surgical resection and radioactive iodine therapy are recommended for OTC patients and FTC patients. It is worth noting that the prognosis of OTC relies largely on the selection of treatment strategies. Therefore, our results highlighted the clinical significance of the early distinguishment and the correct choice of treatment in OTC patients.

Keywords: Follicular thyroid carcinoma; Oncocytic thyroid carcinoma; Prognosis; SEER.

PubMed Disclaimer

Conflict of interest statement

Declarations. Conflict of interest: The authors declare they have no competing interests. Ethical approval: The data analyzed in the present study was collected from the SEER database, which contained the de-identified information for patients; therefore, this article was exempted from approval by the Institutional Review Board.

Similar articles

Cited by

References

    1. Nguyen QT, Lee EJ, Huang MG et al (2015) Diagnosis and treatment of patients with thyroid cancer. Am Health Drug Benefits 8:30–40 - PubMed - PMC
    1. Davies L, Welch HG (2014) Current thyroid cancer trends in the United States. JAMA Otolaryngol Head Neck Surg 140:317–322 - DOI - PubMed
    1. Grani G, Lamartina L, Durante C et al (2018) Follicular thyroid cancer and Hürthle cell carcinoma: challenges in diagnosis, treatment, and clinical management. Lancet Diabetes Endocrinol 6:500–514 - DOI - PubMed
    1. Wu MH, Lee YY, Lu YL et al (2022) Risk factors and prognosis for metastatic follicular thyroid cancer. Front Endocrinol 13:791826 - DOI
    1. Nagar S, Aschebrook-Kilfoy B, Kaplan EL et al (2013) Hurthle cell carcinoma: an update on survival over the last 35 years. Surgery 154(6):1263–1271 - DOI - PubMed

Publication types

MeSH terms

Supplementary concepts

LinkOut - more resources